JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases

Area of Science:

• Biomarker Discovery
• Immunology
• Molecular Biology

Background:

• Inflammation is a key factor in cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers.
• Early stages of inflammation-related diseases are often accompanied by autoantibody development.
• Identifying novel antibody biomarkers is crucial for early disease detection and management.

Purpose of the Study:

• To identify novel autoantibody biomarkers for inflammation-related diseases.
• To investigate the diagnostic and prognostic potential of autoantibodies against Jumonji C-domain-containing 6 (JMJD6).

Main Methods:

• Serological identification of antigens through recombinant cDNA expression cloning identified JMJD6.
• Serum antibody levels were quantified using amplified luminescent proximity homogeneous assay-linked immunosorbent assay with purified recombinant JMJD6.
• Immunohistochemical analysis was performed on patient tissues.

Main Results:

• Elevated serum anti-JMJD6 antibodies (s-JMJD6-Abs) were found in patients with ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and various cancers.
• s-JMJD6-Ab levels correlated with inflammation indicators like C-reactive protein and intima-media thickness.
• JMJD6 was highly expressed in inflamed esophageal tissues, esophageal carcinoma, and atherosclerotic plaques.
• JMJD6-Ab positivity was associated with better postoperative survival in esophageal cancer patients.

Conclusions:

• JMJD6 autoantibodies may serve as valuable biomarkers for diagnosing inflammation-related diseases including stroke, AMI, DM, and cancers.
• These autoantibodies show potential for predicting prognosis in conditions like esophageal cancer.
• JMJD6 expression is linked to inflammatory processes in relevant disease tissues.